Dr. Mark White:

Yes, that is the problem. We are behind our partners on many of the projects because of the timelines. To get an ethics approval in Ireland, for example, some of our members are involved in clinical trials across Europe, we fall way behind our partners, embarrassingly so, at many of the European meetings. The only thing I can see which has raised its head here in Ireland is export control. The types of data that we are creating and how we control and share them across the world is being raised, not by the Department of Health but by the Department of Trade, Enterprise and Employment. We create and generate an awful lot of knowledge and a lot of commercially sensitive and security-sensitive information, even around genomics. One would not think that would create an issue. The research community in Ireland is really grappling with it at the moment. We have not had any shackles put on us before. We have had very liberal approaches to what we do with our data and commercially sensitive information and how we share it with our partners in Europe. There is a whole new spotlight that has come on that in the last six months and it will continue for the next 18 months while we navigate our way through that. However, I do not see anything in Irish legislation precluding us from stepping up to the plate in Europe and playing our part.